Baird Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $58
Guggenheim Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating
Dianthus Therapeutics Analyst Ratings
Oppenheimer Initiates Dianthus Therapeutics at Outperform With $48 Price Target
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target
Promising Clinical Developments Bolster Buy Rating for Dianthus Therapeutics
Wedbush Remains a Buy on Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Receives 'Buy' Rating on Strong Financials and Promising Drug Pipeline
Baird Starts Dianthus Therapeutics With Outperform Rating, $58 Price Target
Dianthus Therapeutics Analyst Ratings
Baird Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $58
Buy Rating on Dianthus Therapeutics Supported by Promising MMN Treatment Data and Market Potential
Dianthus Therapeutics: Katkhuda's Buy Rating Backed by Promising DNTH103 Clinical Prospects and Strategic Positioning
Dianthus Therapeutics Analyst Ratings
Dianthus Therapeutics (DNTH.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $40.00.
Analysts' Opinions Are Mixed on These Healthcare Stocks: 60 Degrees Pharmaceuticals, Inc. (SXTP), GoodRx Holdings (GDRX) and Dianthus Therapeutics (DNTH)
HC Wainwright & Co. Initiates Coverage On Dianthus Therapeutics With Buy Rating, Announces Price Target of $40